Both serum 25-hydroxyvitamin D and calcium levels may increase the risk of incident prostate cancer in Caribbean men of African ancestry

Maria D. Jackson1, Marshall K. Tulloch-Reid2, Carole M. Lindsay3, Garrett Smith3, Franklyn I. Bennett4, Norma McFarlane-Anderson3, William Aiken5 & Kathleen C. M. Coard4

1Department of Community Health & Psychiatry, University of the West Indies, Mona, Kingston, Jamaica
2Tropical Medicine Research Institute, University of the West Indies, Mona, Kingston, Jamaica
3Department of Basic Medical Sciences, University of the West Indies, Mona Campus, Kingston, Jamaica
4Department of Pathology, University of the West Indies, Mona Campus, Kingston, Jamaica
5Department of Surgery, Radiology, Anaesthesia & Intensive Care, University of the West Indies, Mona Campus, Kingston, Jamaica

Keywords
25 hydroxyvitamin D, African ancestry, serum calcium

Abstract
Circulating 25-hydroxyvitamin D [25(OH)D] concentrations have been associated with both higher and lower risk of prostate cancer (PCa), whereas elevated levels of circulating calcium has been related to higher risks. However, there are few studies that account for effects of both calcium and 25(OH)D concentrations on incident PCa in a black population. We examined these relationships in a case–control study of men 40–80 years old with newly diagnosed, histologically confirmed PCa in Jamaica, a tropical country. Mean serum calcium concentrations was higher among cases (2.32 ± 0.19 mmol/L) than controls, (2.27 ± 0.30 mmol/L) (P = 0.023) however, there were no differences in 25(OH)D by cancer status (cases, 33.67 ± 12.71 ng/mL; controls (32.25 ± 12.59 ng/mL). Serum calcium was not correlated with 25(OH)D (partial correlation: r, 0.06; P = 0.287). Multivariable-adjusted models showed a positive linear relationship between PCa and serum calcium (OR, 1.12; CI, 1.00–1.25 per 0.1 nmol/L). Serum 25(OH)D concentration also showed a positive association with PCa (OR, 1.23; CI, 1.01–1.49 per 10 ng/mL). The odds of PCa in men with serum 25(OH)D tertile 2 was OR, 2.18; CI, 1.04–4.43 and OR, 2.47 CI, 1.20–4.90 for tertile 3 (Ptrend = 0.013). Dietary intakes of calcium showed no relationship with PCa. Despite the strong relationship between serum calcium and vitamin D the mechanism by which each affects prostate cancer risk in men of African ancestry needs additional investigation.

Introduction
Cancer of the prostate is the leading cancer site for Jamaican men [1] and few modifiable risk factors have been found to be consistently associated with the disease. Vitamin D has been emerging as one of these modifiable risk factors that play an important role in the development of the prostate cancer (PCa) particularly in men of African origin [2–4]; however, the mechanisms for the effect of vitamin D on this disease are not completely understood.

In vivo and in vitro studies demonstrate that Vitamin D may work by inhibiting cell proliferation [5] cell migration [6], metastasis and angiogenesis [7, 8]. However, in Xu et al.’s recent meta-analyses 25-hydroxyvitamin D [25(OH)D] and PCa in predominantly white populations suggests that vitamin D may increase the risk of PCa [4], contradicting the findings from earlier meta-analyses of observational studies which showed no evidence of an association between 25(OH)D and PCa [9–11]. Schwartz’s systematic review indicated that low 25(OH)D levels
increased the risk of fatal PCa [12] and supports ecological studies which suggest higher vitamin D was associated with lower PCa incidence [13]. Two nested case-control studies showed that high vitamin D concentrations were associated with increased risk of PCa [2, 14] while among African-American men higher vitamin D predicted reduced risk of high-grade disease [14].

Vitamin D is obtained primarily through the synthesis of 7-dehydrocholesterol in the skin exposed to UVB radiation and to a lesser extent, diet (natural foods and fortified products) and supplements [15]. Subsequent to synthesis in the skin or ingestion, vitamin D is converted to 25(OH)D in the liver and to the biologically active form, 1,25-dihydroxyvitamin [1,25(OH)2D] [16] in the kidneys. 25(OH)D, the predominant circulating metabolite, is influenced by latitude, skin color, and age and is a good marker of vitamin D [17] status. Prostate cells which contain vitamin D receptor (VDRs) can synthesize a small proportion of this vitamin and may respond to 1, 25(OH)2D with increased differentiation and apoptosis and decreased proliferation, invasiveness, and metastasis [18].

Vitamin D [1, 25(OH)2D], is known to exert control on calcium homeostasis. Elevated levels of calcium could result in increased differentiation and proliferation in PCa cells [19]. In experimental studies, calcium has been shown to promote the proliferation and metastasis of PCa cells through the calcium sensing receptors (CaSR) on the gland [20, 21]. Calcium may also work synergistically with hormones such as insulin-like growth factors [22] and estrogens [23] in foods, to influence PCa development. High intake of calcium from dairy products is hypothesized to downregulate the active form of vitamin D, [1,25(OH)2D] [24] thereby promoting the development of metastases [7].

There is relative inattention to circulating vitamin D and calcium and PCa risk in populations of African ancestry. Furthermore, the associations of 25(OH)D and calcium concentrations with the incidence of PCa in geographic locations with high irradiance exposure are less clear as few studies have investigated these relationships. In this report we determine the relationship of both circulating concentrations of serum calcium and 25(OH)D with prostate cancer in Jamaica, a predominantly black population (91.6%) [25] and among whom PCa is the leading cancer and the principal cause of cancer mortality [1]. We further investigate whether any effect demonstrated is modified by or independent of the other.

Material and Methods

Study population

This case-control study has been described in detail in earlier reports [26]. Briefly men aged 40–80 years old attending urology clinics at two major hospitals and private urologists’ offices in the Kingston Metropolitan area in Jamaica were recruited consecutively and screened for PCa. These sites receive referrals from primary care clinics, hospitals, and private practitioners, island-wide. Routinely, men 40 years and older presenting to the urology clinics/practitioners’ offices are asked to do a prostate-specific antigen (PSA) test regardless of presentation.

Selection of cases and controls

Cases and controls attended the same urology outpatient clinics/offices and were enrolled consecutively.

Cases

Cases were men with newly diagnosed, histologically confirmed PCa and stratified into low-grade and high-grade PCa based on Gleason scores (GS): high-grade, ≥7 and low-grade, GS < 7 [27].

Controls

Control subjects presented with diagnostic conditions that were primarily related to lower urinary tract symptoms and urinary stones or were referred for investigation and treatment of other suspected genitourinary malignancies or disorders (e.g., male-factor infertility); there were few reports of erectile dysfunction or decreased libido as the primary complaint.

Subjects were assigned as controls based on a digital rectal examination (DRE) and total PSA concentration. Controls were initially defined as men with total PSA <2.0 μg/L (n = 176) but subsequently men with total PSA 2.0–4.0 μg/L and free: total PSA >0.15 (n = 99) were also included as controls. Data were collected between March 2005 and July 2007.

Exclusion criteria

Men with locally advanced and metastatic PCa, previous prostate surgery, with recent severe weight loss, on hormonal treatment or taking Finasteride were excluded from the study.

The study was approved by the Ethics committee of the University of the West Indies and the Ministry of Health. Subjects gave written informed consent prior to enrollment.

Data collection

Men enrolled in the study were first-time clinic attendees who were interviewed before a pathological diagnosis was obtained. Measurements and interviews were conducted...
by trained research nurses. Nine hundred and seventy-two men were interviewed and 243 men with newly diagnosed PCa and 275 controls were enrolled; negative biopsy men \((n = 187)\) and men who did not meet the inclusion criteria for controls \((n = 267)\) were excluded from analyses. In this report, we present information on calcium \((224\) cases; \(248\) controls) and \(25(OH)D\) vitamin D \((146\) cases; \(191\) controls) for whom a sample of blood was available. Comparison of the demographic characteristics of subjects with and without a sample of blood for calcium investigations showed that they were similar whereas for vitamin D, men for whom data were available were somewhat older \((P = 0.062)\).

**Measurements**

The examination included anthropometric assessment (weight, height, waist, and hip circumference) and a questionnaire that included items on medical history and lifestyle variables (cigarette smoking, and physical activity). Medical charts and pathology reports were examined to ensure controls did not have a prior history of cancer. Information on demographic and socioeconomic factors was obtained by questionnaire. Body mass index (BMI) was calculated as weight (kg) divided by height \((m)^2\) [28]. A nonfasting blood sample was collected for biologic measurements.

**Laboratory assays**

The blood samples collected were placed on ice-packs in a cooler before being processed and stored. Samples from cases and controls were analyzed together within batches to reduce the effect of interassay variability. Laboratory personnel were blinded to disease status.

**Serum calcium**

Serum calcium concentrations were measured on an Abbott C8000 by the Arsenazo 111 method at the University of the West Indies Pathology (Chemical Pathology) Laboratory. The intra-assay coefficient of variation (CV) was 7.9%.

**Serum 25(OH)D**

Serum \(25(OH)D\) concentration was determined by ultra-performance liquid chromatography/tandem mass spectrometry (UPLC/MS/MS) analysis as outlined by [29] using a Waters ACQUITY TQD System (Waters Corporation, Milford, USA) fitted with an ACQUITY UPLC BEH Phenyl column \((2.1 \times 50 \text{ mm} \times 1.7 \mu\text{m})\). The instrument was operated in a positive electrospray ionization mode using MassLynx™ software with data processing by the TargetLynx™ Application manager. Standards were purchased from 1017 West Ninth AvenueKing of Prussia, PA 19406USA (PA). All other reagents and chemicals were obtained from SIGMA-ALDRICH CORPORATION3050 SPRUCE STSAINT LOUIS MO 63103 US.

**Assay performance**

Assay precision was determined by extracting and quantifying five replicates of a quality control sample and the CV was found to be 11%. The recovery of \(25(OH)D_3\) was > 90% over the analytical range of the assay. The limit of detection (LOD) for the assay was 0.5 ng/mL and the limit of quantitation (LOQ) was 2.2 ng/mL. The calibration curve was linear over the working range with a correlation coefficient of 0.996.

**Dietary intakes**

Dietary intakes were assessed by use of an interviewer-administered validated 120-item food frequency questionnaire (FFQ) that was developed to assess diet and cancer in the Jamaican population [30]. In addition to frequency of consumption for each food item, subjects were asked to estimate the portion size usually consumed by using food models, commonly used household utensils, measuring cups and a measuring tape.

**Statistical analysis**

Chi-square statistics or Fisher’s exact test were used to examine differences between cases and controls for categorical variables and the Mann–Whitney \(U\)-test, or \(t\)-test was used for continuous data. Serum calcium and \(25(OH)D\) were categorized into tertiles based on the distribution among the controls. In addition, \(25(OH)D\) data were analyzed using reference cut-points that included levels of deficiency/sufficiency of <20 ng/mL (deficiency), 20–29 ng/mL (insufficiency) and >30 ng/mL (sufficiency) as suggested by Holick et al. [31], however, we were underpowered (13 cases and 3 controls) to examine relationship between serum calcium above 2.57 mmol/L and \(25(OH)D\).

Differences between outcome variables (tertiles of serum and dietary calcium and \(25(OH)D\) and socioeconomic variables, medical history, and lifestyle were explored using chi-square statistics and Fisher’s exact test for categorical variables and analysis of variance was used for continuous data. Tests for linear trends across tertiles of serum \(25(OH)D\) and calcium were performed using the Wald \(\chi^2\) statistic.

Logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CIs) for PCa according to per unit change and by tertiles of \(25(OH)D\) and serum
and dietary calcium. Analyses were conducted with all PCa cases and compared with all control subjects. In multivariable analysis, adjustment was made for age and BMI (continuous), education (primary or less, secondary, tertiary—a measure of socio-economic status), family history of PCa in first degree relatives (yes, no), physical activity (inactive/moderately inactive, moderately active/active), current smoking (yes, no), and supplement use (primarily vitamins) in our analyses. In addition, we examined whether the association between serum calcium and PCa was modified by 25(OH)D, age, BMI (<25 or ≥25 kg/m²), or smoking (current or non-, ex-smoker) by creating a cross-product term between serum calcium and the potential effect modifier. Likelihood ratio tests were used to test for evidence of effect modification. Similar tests were employed for 25(OH)D and included physical activity as a potential effect modifier.

All analyses were performed using the Statistical Package for Social Sciences (SPSS. Statistical Package for Social Scientists, version 19.0. Chicago: SPSS Inc. 2010.) version 19.0. Statistical significance was achieved when \( P < 0.05 \).

### Results

#### Study characteristics

Men with PCa were on average 5 years older than controls (cases, 67.6 ± 7.8; controls, 62.3 ± 10.5 years) (Table 1). With the exception of cases being significantly shorter (cases, 169.6 ± 6.6 cm; controls, 171.5 ± 7.0 cm) and less educated, both groups had similar mean BMI, waist and hip circumference, and waist-hip ratio. Just over one-half of PCa cases were high grade and significantly more men with PCa than controls reported that they were previously screened for the disease.

Serum concentrations of calcium were higher among cases (2.32 ± 0.19 nmol/L) than controls (2.27 ± 0.30 nmol/L; \( P = 0.027 \)). Cases and controls did not differ in mean serum 25(OH)D vitamin D level (cases, 33.67 ± 12.59 ng/mL; controls, 32.25 ± 12.71 ng/mL, \( P = 0.300 \)) (Table 1).

Table 2 shows tertiles of serum calcium concentration according to selected characteristics of the sample. Mean concentrations of serum calcium in tertiles 1–3 were

| Table 1. Characteristics of cases and controls. |
|-----------------------------------------------|
| Controls (n = 248) | Cases (n = 224) | \( P \) |
| Socio-demographic | | |
| Age: mean ± SD (years) | 62.3 ± 10.5 | 67.6 ± 7.8 | 0.0001 |
| Education: % (n) | | |
| Primary or less | 80.8 | 90.3 | 0.003 |
| Secondary or higher | 19.2 | 9.7 | |
| Anthropometry | | |
| Weight (kg) | 74.5 ± 14.5 | 72.4 ± 13.7 | 0.092 |
| Height (cm) | 171.5 ± 7.0 | 169.6 ± 6.6 | 0.003 |
| Waist circumference: mean ± SD | 84.4 ± 12.7 | 88.0 ± 12.2 | 0.590 |
| Body mass index (BMI) kg/m² | 25.1 ± 4.3 | 21.5 ± 4.6 | 0.852 |
| BMI categories | | |
| ≤24.99 | 52.1 | 54.5 | 0.576 |
| 25.00–29.99 | 37.1 | 31.4 | |
| ≥30.00 | 10.8 | 14.1 | |
| Medical/behavioral | | |
| Cases only: % (n) | | |
| Low-grade prostate cancer¹ | – | 42.7 | |
| High-grade prostate cancer² | – | 54.0 | |
| Unknown | – | 3.3 | |
| PSA: µg/L median (25th, 75th percentile) | 1.6 (0.8, 3.5) | 25.8 (12.0, 100.1) | 0.0001 |
| Previous PSA screens: % | 59.0 | 88.6 | 0.0001 |
| Previous DRE: % | 75.0 | 85.9 | 0.005 |
| Family history of prostate cancer: % | 11.1 | 16.3 | 0.113 |
| Current smoker: % | 16.8 | 13.2 | 0.508 |
| Supplement use: % | 29.5 | 23.5 | 0.185 |
| Serum calcium (nmol/L): mean ± SD (median) | 2.27 ± 0.30 (2.31) | 2.32 ± 0.19 (2.34) | 0.027 |
| Serum 25(OH)D (ng/mL): mean ± SD (median) | 32.25 ± 12.59 (30.8) | 33.67 ± 12.71 (32.1) | 0.300 |

PSA, prostate-specific antigen; DRE, digital rectal examination.

¹Low-grade cancer indicates Gleason score of <7.

²High-grade cancer indicates Gleason score of ≥7.
2.11 ± 0.13, 2.30 ± 0.04, and 2.48 ± 0.10 mmol/L, respectively. Men in the highest tertile of serum calcium when compared to their counterparts in the lowest tertile reported similar educational achievement and levels of physical activity. Men in tertile 3 were less likely to report a family history of PCa and men in tertile 2 were less likely to report current smoking. Those in the first tertile showed significantly lower mean BMI than men in the upper 2 tertiles.

Mean concentrations of serum 25(OH)D in tertiles 1–3 were 20.54 ± 5.06, 30.62 ± 2.06, and 45.43 ± 11.31 ng/mL, respectively (Table 2). The characteristics of men did not vary by other demographic or lifestyle variables. Examination of these variables by 25(OH)D reference cut-points showed that men were similar in characteristics, however, with the small sample size in some groups we may have been underpowered to detect any differences.

### Table 2. Characteristics of men according to tertiles of serum concentration calcium and vitamin D.

| Categories of serum concentrations | Participants: n | Age: years | Education: % | Family history of prostate cancer: % | Current smoker: % | Physical activity: % | Supplement use: % | Serum vitamin D (ng/mL)1 | Participants: n | Age: years | Education: % | Family history of prostate cancer: % | Current smoker: % | Physical activity: % | Supplement use: % |
|-------------------------------------|----------------|-----------|---------------|---------------------------------------|------------------|---------------------|------------------|------------------------|----------------|-----------|---------------|---------------------------------------|------------------|---------------------|------------------|
| Serum calcium (mmol/L)1             |                |           |               |                                       |                  |                     |                  |                        |                |           |               |                                       |                  |                     |                  |
| ≤2.23                               | 135            | 64.8 ± 10.1 | 83.9          | 13.5                                  | 16.5             | 46.7                | 23.2             | 27.06                  | 106            | 64.9 ± 9.7 | 77.9          | 14.8                                  | 14.0             | 47.1                | 29.3             |
| 2.24–2.37                           | 172            | 64.4 ± 9.5 | 81.5          | 12.9                                  | 12.2             | 43.9                | 31.7             | 27.07–34.26           | 117            | 64.8 ± 10.2 | 86.1          | 13.9                                  | 13.9             | 41.7                | 26.8             |
| 2.38–3.01                           | 165            | 65.4 ± 9.7 | 88.7          | 10.3                                  | 15.2             | 25.7                | 25.0             | 34.27–93.20           | 125            | 64.1 ± 9.7 | 88.5          | 9.6                                   | 15.2             | 51.6                | 36.6             |
| Serum calcium (mmol/L) (mean ± SD)***|                |           |               |                                       |                  |                     |                  |                        |                |           |               |                                       |                  |                     |                  |
| 2.11 ± 0.13                         |                 |           | 2.30 ± 0.04   |                                       |                  |                     |                  |                        |                 |           | 2.48 ± 0.10   |                                       |                  |                     |                  |
| Participants: n: n = 12             |                 |           | 83            |                                       |                  |                     |                  |                        |                 |           | 1014           |                                       |                  |                     |                  |
| Age: years                          |                 |           | 64.9 ± 10.1   |                                       |                  |                     |                  |                        |                 |           | 64.8 ± 9.5    |                                       |                  |                     |                  |
| Education: %                         |                 |           |               |                                       |                  |                     |                  |                        |                 |           |               |                                       |                  |                     |                  |
| Primary or less                      |                 |           | 83.9          |                                       |                  |                     |                  |                        |                 |           | 77.9          |                                       |                  |                     |                  |
| Secondary or higher                 |                 |           | 16.1          |                                       |                  |                     |                  |                        |                 |           | 22.1          |                                       |                  |                     |                  |
| Family history of prostate cancer: %|                 |           | 13.5          |                                       |                  |                     |                  |                        |                 |           | 14.8          |                                       |                  |                     |                  |
| Current smoker: %                   |                 |           | 16.5          |                                       |                  |                     |                  |                        |                 |           | 14.0          |                                       |                  |                     |                  |
| Physical activity: %                |                 |           |               |                                       |                  |                     |                  |                        |                 |           |               |                                       |                  |                     |                  |
| Inactive/moderately inactive        |                 |           | 46.7          |                                       |                  |                     |                  |                        |                 |           | 47.1          |                                       |                  |                     |                  |
| Moderately active/active            |                 |           | 53.3          |                                       |                  |                     |                  |                        |                 |           | 52.9          |                                       |                  |                     |                  |
| Body mass index (BMI) kg/m²*        |                 |           | 24.1 ± 4.2    |                                       |                  |                     |                  |                        |                 |           | 25.7 ± 4.9    |                                       |                  |                     |                  |
| Supplement use: %                   |                 |           | 23.2          |                                       |                  |                     |                  |                        |                 |           | 58.3          |                                       |                  |                     |                  |
| Serum 25(OH)D (ng/mL)1              |                 |           | ≤27.06        |                                       |                  |                     |                  |                        |                 |           | 25.2 ± 4.3    |                                       |                  |                     |                  |
| Participants: n: n = 12             |                 |           | 20.54 ± 5.06  |                                       |                  |                     |                  |                        |                 |           | 25.7 ± 4.9    |                                       |                  |                     |                  |
| Age: years                          |                 |           | 64.9 ± 9.7    |                                       |                  |                     |                  |                        |                 |           | 64.8 ± 10.2   |                                       |                  |                     |                  |
| Education: %                         |                 |           |               |                                       |                  |                     |                  |                        |                 |           |               |                                       |                  |                     |                  |
| Primary or less                      |                 |           | 77.9          |                                       |                  |                     |                  |                        |                 |           | 77.9          |                                       |                  |                     |                  |
| Secondary or higher                 |                 |           | 22.1          |                                       |                  |                     |                  |                        |                 |           | 22.1          |                                       |                  |                     |                  |
| Family history of prostate cancer: %|                 |           | 14.8          |                                       |                  |                     |                  |                        |                 |           | 14.8          |                                       |                  |                     |                  |
| Current smoker: %                   |                 |           | 14.0          |                                       |                  |                     |                  |                        |                 |           | 14.0          |                                       |                  |                     |                  |
| Physical activity: %                |                 |           |               |                                       |                  |                     |                  |                        |                 |           |               |                                       |                  |                     |                  |
| Inactive/moderately inactive        |                 |           | 47.1          |                                       |                  |                     |                  |                        |                 |           | 47.1          |                                       |                  |                     |                  |
| Moderately active/active            |                 |           | 52.9          |                                       |                  |                     |                  |                        |                 |           | 58.3          |                                       |                  |                     |                  |
| BMI kg/m²                           |                 |           | 25.7 ± 4.9    |                                       |                  |                     |                  |                        |                 |           | 25.7 ± 4.9    |                                       |                  |                     |                  |
| Supplement use: %                   |                 |           | 29.3          |                                       |                  |                     |                  |                        |                 |           | 26.8          |                                       |                  |                     |                  |

Tertiles based on values of controls.

*P < 0.05; ***P < 0.0001.

Dietary calcium and PCa

In this report, we excluded from analyses subjects whose reported intakes were outside the range of 800–5000 kcal (n = 12) or who provided incomplete information on the FFQ (n = 83). A total of 184 cases and 239 controls were used for analyses of diet.

Cases and controls reported similar intakes of calcium (dietary calcium: cases, 1041 ± 411; controls, 1022 ± 412). Table 3 presents information on dietary intakes of calcium stratified by reference cut-points and shows participants reported similar educational achievement and supplement use with increasing dietary calcium intake. However, more men with calcium intakes at the recommended and higher levels reported that they were moderately active/active. Energy, phosphorous, and vitamin D intakes increased with increasing calcium intake.

Major food sources of calcium (percentage contribution) to total calcium intake were: cereals (17.0%), vegetables (16.9%), fruits (11.2%), dairy products (9.3%), and seafood (5.8%). Soy or soy products were not significant contributors to calcium intake (0.4%) (data not shown).

Dietary calcium intakes were examined to determine their association with risk of PCa and showed no evidence that dietary intakes were associated with the disease (Table 4). Intakes of ≤1000 mg and >1000 mg calcium

© 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
daily, showed no relationship with PCa risk (OR, 0.75 CI, 0.44–1.30) (data not shown).

### Serum calcium and 25(OH)D with risk of PCa

Table 5 displays age-adjusted and multivariable-adjusted estimates for serum calcium as a continuous variable with risk of PCa. Serum calcium was positively correlated with PCa diagnosis (multivariable-adjusted: OR, 1.12; CI, 1.01–1.49 per 0.1 nmol/L). There were no significant interactions between PCa, calcium and any of the other factors examined including age, BMI, or a family history of PCa.

With control for age, education, smoking, BMI, supplement use, and family history of the disease, men in the second and third tertiles of serum 25(OH)D had an increased odds of PCa (tertile 2: OR, 1.42; CI, 1.04–1.99) (tertile 3: OR, 2.47 CI, 1.20–4.90; $P_{\text{trend}} = 0.013$) (Table 5). As a continuous variable, higher 25(OH)D was related to increased likelihood of PCa (OR, 1.23; CI, 1.01–1.49 per 10 ng/mL). We investigated the relationship between 25(OH)D and PCa using cut-points based on reference values (<20, 20–29, and >30 ng/mL; cases/controls: 16/27, 44/67, 93/103, respectively). Examination of 25(OH)D in which men in lowest tertile of the metabolite served as the reference group showed that men in the higher tertiles had nonsignificant increased odds for PCa (tertile 2: OR, 1.42; CI, 0.52–7.94) (tertile 3: OR, 2.47; CI, 0.97–6.28). Partial correlations (age-adjusted) showed no linear relationship between serum concentrations of vitamin D and calcium ($r$, 0.09; $P = 0.287$).

### Discussion

In this study of men of predominantly African ancestry, we investigated the independent associations of serum
Serum Calcium and Vitamin D and PCa

Table 5. Odds ratios and 95% CIs for association of serum calcium and 25 (OH)D with total prostate cancer.

| Categories of serum concentrations | Serum calcium (mmol/L)1 | 25 (OH)D (ng/mL)1 | Serum calcium per 0.1 nmol/L |
|------------------------------------|------------------------|-------------------|-----------------------------|
| Serum calcium (mmol/L)1            | ≤2.23                  | <27.06            | 2.23–2.27                   |
| Total prostate cancer              | 2.44–2.37              | 27.07–34.26       | 2.38–3.01                   |
| Cases/controls                     | 61/78                  | 41/65             |                             |
| Age-adjusted OR (95% CI)           | 1.0 (ref.)             | 1.0 (ref.)        |                             |
| Multivariable-adjusted2,3         | 1.0 (ref.)             | 1.0 (ref.)        |                             |
| 25 (OH) vitamin D (ng/mL)1         | <27.06                  | <27.06            | <27.06                      |
| Total prostate cancer              | 27.07–34.26            | 34.27–39.20       | 34.27–39.20                 |
| Cases/controls                     | 41/65                  | 52/65             | 60/65                       |
| Age-adjusted OR (95% CI)           | 1.0 (ref.)             | 1.29 (0.73–2.27)  | 1.68 (0.96–2.94)            |
| Multivariable-adjusted2,3         | 1.0 (ref.)             | 2.18 (1.04–4.43)  | 2.47 (1.20–4.90)            |

1Tertiles based on values of controls.
2Adjusted for age and BMI as continuous, education (primary or less, secondary, higher), family history of prostate cancer (no/yes), physical activity (inactive/moderately inactive active, moderately active/active), smoking (nonsmoker, ex-smoker, current smoker) and supplement use (no/yes).
3Also adjusted for 25(OH)D and serum calcium as appropriate.

calcium and 25(OH)D on PCa risk. We found a dose-dependent relationship with serum 25(OH)D and PCa. Our data showed that each 10 ng/mL increase in 25(OH)D was associated with a 23% increased risk PCa. Serum calcium was associated with a 12% increased risk of PCa for 0.1 mmol/L difference in the metabolite. Serum calcium showed no linear relationship with 25(OH)D (r, 0.09; P = 0.287) and there was no evidence of interaction between vitamin D and serum calcium and the risk of PCa. Thus, when considered independently, serum calcium and 25(OH)D showed linear associations with PCa risk and appeared to function independently of the other.

Concentrations of serum calcium found in this study compared well to men in the National Health and Nutrition Examination Survey (NHANES) [32, 33] and the Malmo Preventive Project [34]. Our findings that higher serum calcium concentrations increased the risk of incident PCa are consistent with laboratory studies that show that calcium promotes growth of PCa cells [21]. There are few epidemiologic studies on serum calcium and incident PCa [32, 34–37]. The Malmo Diet and Cancer Study cohort showed a positive relationship between albumin-adjusted calcium and PCa among men aged 55–65 with a BMI <25.0 kg/m² (relative risk, 2.07; CI, 1.08–3.97) [35]. Halthur et al. found that, whereas there was no evidence of an overall association between prediagnostic concentrations of serum calcium and risk of PCa in Swedish men (HR, 0.94; 95% CI, 0.81–1.09), young (<45 years) overweight men appeared to have decreased risk of developing PCa [34].

Using the prospective cohorts of the first NHANES and the NHANES Epidemiologic Follow-up Study in which 85 cases were identified, Skinner and Schwartz [32] reported that serum calcium was not a significant predictor of incident PCa (HR, 1.31; 95% CI, 0.77–2.20). In contrast, data from the Swedish Apolipoprotein Mortality RISK study suggested a protective association with calcium or albumin-corrected calcium and PCa risk (HR, 0.91; 95% CI, 0.85–0.98) [37]. Bristow et al.’s meta-analysis of randomized controlled trials of calcium supplements on cancer risk showed that supplementation was not associated with risk of overall cancer risk, but for the few events of PCa they recorded an inverse relationship with calcium supplementation (RR, 0.54; 95% CI, 0.30–0.96) [38].

We found nonsignificant relationships between dietary calcium intake and PCa whether using absolute cut-points or by calcium intake tertiles. The mean dietary calcium intake (1000 mg/day) of participants satisfied the Institute of Medicine Recommended Dietary Allowance for men aged 51–70 years [39] with 2.7% of subjects reporting extremely high intakes, that is, ≥2000 mg/day. Huncharek et al.’s meta-analysis of cohort studies showed a weak positive relationship between dietary calcium and PCa risk and found no association in case-control studies (RR, 1.04; 95% CI, 0.90–1.15) [40]. More recently, Williams et al.’s study of US veterans and healthy controls showed that total calcium intake (median intake, 708 mg/day) was protective of PCa among Blacks but not Whites [41]. Rowland et al.’s study of African Americans and Whites showed that low calcium intake (<604 mg/day) was inversely related to PCa risk among men with the VDR Gdx2 GG genotype that has been linked to low calcium absorption [42]. It is possible therefore, that the increased risk observed in this study may be related to factors such as the genetic variation in CaSR genes that control serum calcium levels [43].

Our finding of vitamin D as a risk factor for PCa is consistent with Xu’s recent meta-analysis that showed
higher 25(OH)D concentration increased the risk of PCa (OR, 1.17; 95% CI: 1.05–1.30; \( P = 0.004 \)) [4]. Earlier meta-analyses by Gandini [9], Gilbert et al. [10] and Yin et al. [11] highlighted nonsignificant relationships. In the Selenium and Vitamin E Cancer Prevention Trial (SELECT) the association with plasma vitamin D was U shaped indicating that both high and low vitamin D concentrations were associated with PCa and among African-American men high concentration of the metabolite predicted reduced risk of high-grade disease [2]. Weinstein et al.'s examination of the association between 25(OH)D and the primary transporter of vitamin D compounds in the circulation, vitamin D-binding protein (DBP) and PCa showed that serum vitamin D was associated with higher risk of PCa (OR, 1.47; 95% CI: 1.07–2.02), and the association was stronger when DBP levels were higher (OR, 1.81, 95% CI: 1.18–2.79) compared with lower (OR, 1.22; 95% CI: 0.81–1.84; \( P_{\text{interaction}} = 0.04 \)) thereby indicating that DBP modified the association between 25(OH)D and PCa [44].

In the present study, 2.9% of subjects (cases, 4; controls, 6) had 25(OH)D concentrations \( \leq 12 \) ng/mL; 12.4% and of men were 25(OH)D \( < 20 \) ng/mL indicating levels of deficiency (data not shown). At higher concentrations \( \geq 8\% \) of subjects (cases, 12; controls, 16) had 25(OH)D \( \geq 50 \) ng/mL hence the group may be underpowered to detect an association using these categorizations. Murphy et al.’s examination of prostate biopsy outcomes with 25(OH)D reported that 25(OH)D \( < 20 \) ng/mL was associated with increased odds of PCa diagnosis on biopsy [45]. Our findings confirm reports that suggest that 25(OH)D increases the likelihood of PCa. It is unclear, however, the extent to which circulating 25(OH)D reflects intraprostatic vitamin D concentrations [12].

Serum vitamin D concentrations in our population were comparably higher than levels reported in Caucasians in Europe [46–48] and men of African ancestry in the United States [46–49] but compared well to men in similar geographic location [50]. In this study, almost 60% of men had 25(OH)D concentrations at biologically normal levels \( \geq 30 \) ng/mL; 0.3% of subjects had 25(OH)D concentrations \( > 90 \) ng/mL. Observational studies suggest that pigmentary characteristics such as dark skin are likely to inhibit vitamin D synthesis as melanin blocks the initial conversion of 7-dehydrocholesterol to cholecalciferol, the precursor of 25(OH)D in the skin [51]. Genetic studies of ancestry and 25(OH)D insufficiency show an inverse relationship between African ancestry and 25(OH)D [49]. Gilbert et al.’s study in the UK reported that with adjustment for potential confounding factors such as age and skin pigmentation, men with exposures suggesting reduced levels of cutaneous vitamin D synthesis had lower risk of advanced or high-grade disease and further suggested that men with olive/brown skin were at increased risk of PCa [52]. Jamaica is a tropical environment with high solar exposure throughout the year. With geographic coordinates of 18°15’N and 77°30’W, the island records on average \( \approx 8.2 \) h of sunlight daily hence seasonal variability is not expected to influence the availability of 25(OH)D. Gilbert et al.’s meta-analysis of life course exposure to sunlight with PCa showed weak evidence that low exposure to sunlight was related to PCa risk [52]. At present, a role for 25(OH)D in modifying PCa has not been well defined and it is unclear whether high 25(OH)D status is causally related to the disease or a marker of ill-health. There is need to identify a clear biological relationship between high vitamin D and PCa risk.

**Strengths/limitations**

We examined the association of serum calcium and 25(OH)D with overall PCa in a predominantly Afro-ethnic population with high UV exposure and is one of the first studies to examine these relationships in the Caribbean. We measured serum 25(OH)D, an indicator of dietary intake and sun exposure. Our data reflected the consumption of multivitamins in general and did not ask specific questions on vitamin D supplements, which could affect the values. We did not evaluate for the presence of renal or liver diseases or hyperparathyroidism in our subjects which may also affect serum Vitamin D and calcium. These conditions are associated with low vitamin D levels, [53–55] however, we do not believe that it resulted in a detection bias as 12.4% of men had 25-(OH)D concentrations <20 ng/mL.

Similar to other epidemiologic studies, there is uncertainty of the extent to which 25(OH)D reflects intraprostatic vitamin D levels as 1,25(OH)2D through it local production in prostate cells expressing 25(OH)-1α-hydroxylase enzyme [56]. Additionally, it is possible that 25(OH)D may be a marker for other factors such as insulin-like growth factor-1 which associated with 25(OH)D and has been related to PCa [57]. We measured a single sample of 25(OH)D and calcium and samples representing different time points are likely to give more precise estimates of exposures. Our study was case-control in design hence a temporal relationship between dietary intakes, serum calcium, and vitamin D and PCa cannot be established, however, the design of the study with the use of incident PCa and assessment of the participants prior to any knowledge of a PCa diagnosis strengthen our conclusions. Our findings are valid within an African ancestry population and cannot be extrapolated to other ethnic groups, given the previously reported heterogeneity by pigmentary characteristics [17].
Conclusion

Our results suggest that serum calcium and 25(OH)D may independently increase the likelihood of PCa among men of African ancestry. Well-designed studies (specifically cohort studies) among Blacks are required to confirm the relationship between circulating 25(OH)D and calcium in the development of PCa in Blacks and explore possible mechanisms in the causal pathway.

Acknowledgments

This work was supported by the National Health Fund (HSF19), CHASE Fund and the Planning Institute of Jamaica (77/854). This study was supported also in part by grants from the Anthony N Sabga (ANSA) Award awarded to K. C. M. C. The authors thank the study participants and research nurses, Barbara Panton, Elsa Brown, Nicola Meeks-Aitken, Donnahae Rhoden-Salmon, and study participants for their support in the investigation.

Conflict of Interest

None declared.

References

1. Gibson, T. N., G. Blake, B. Hanchard, N. Waugh, and D. McNaughton. 2008. Age-specific incidence of cancer in Kingston and St Andrew, Jamaica, 1998–2002. West Indian Med. J. 57:81–89.
2. Kristal, A. R., C. Till, X. Song, C. M. Tangen, P. J. Goodman, M. L. Neuhauser, et al. 2014. Plasma vitamin D and prostate cancer risk: results from the Selenium and Vitamin E Cancer Prevention Trial. Cancer Epidemiol. Biomarkers Prev. 23:1494–1504.
3. Platz, E. A., E. B. Rimm, W. C. Willett, P. W. Kantoff, and E. Giovannucci. 2000. Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. J. Natl. Cancer Inst. 92:2009–2017.
4. Xu, Y., X. Shao, Y. Yao, L. Xu, L. Chang, Z. Jiang, et al. 2014. Positive association between circulating 25-hydroxyvitamin D levels and prostate cancer risk: new findings from an updated meta-analysis. J. Cancer Res. Clin. Oncol. 2014 140:1465–77.
5. Moreno, J., A. V. Krishnan, and D. Feldman. 2005. Molecular mechanisms mediating the anti-proliferative effects of Vitamin D in prostate cancer. J. Steroid Biochem. Mol. Biol. 97:31–36.
6. Sung, V., and D. Feldman. 2000. 1,25-Dihydroxyvitamin D3 decreases human prostate cancer cell adhesion and migration. Mol. Cell. Endocrinol. 164:133–143.
7. Lokeshwar, B. L., G. G. Schwartz, M. G. Selzer, K. L. Burnstein, S. H. Zhuang, N. L. Block, et al. 1999. Inhibition of prostate cancer metastasis in vivo: a comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089. Cancer Epidemiol. Biomarkers Prev. 8:241–248.
8. Bao, B. Y., S. D. Yeh, and Y. F. Lee. 2006. 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell invasion via modulation of selective proteases. Carcinogenesis 27:32–42.
9. Gandini, S., M. Boniol, J. Haukka, G. Byrnes, B. Cox, M. J. Sneyd, et al. 2011. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int. J. Cancer 128:1414–1424.
10. Gilbert, R., R. M. Martin, R. Beynon, R. Harris, J. Savovic, L. Zuccolo, et al. 2011. Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and dose-response meta-analysis. Cancer Causes Control 22:319–340.
11. Yin, L., E. Raum, U. Haug, V. Arndt, and H. Brenner. 2009. Meta-analysis of longitudinal studies: serum vitamin D and prostate cancer risk. Cancer Epidemiol. Biomarkers Prev. 18:2795–2803.
12. Schwartz, G. G. 2013. Vitamin D, sunlight, and the epidemiology of prostate cancer. Anticancer Agents Med Chem 13:45–57.
13. Grant, W. B. 2013. Update on evidence that support a role of solar ultraviolet-B irradiance in reducing cancer risk. Anticancer Agents Med Chem 13:140–146.
14. Schenk, J. M., C. A. Till, C. M. Tangen, P. J. Goodman, X. Song, K. C. Torkko, et al. 2014. Serum 25-hydroxyvitamin D concentrations and risk of prostate cancer: results from the Prostate Cancer Prevention Trial. Cancer Epidemiol. Biomarkers Prev. 23:1484–1493.
15. Haddad, J. G. Jr, and T. J. Hahn. 1973. Natural and synthetic sources of circulating 25-hydroxyvitamin D in man. Nature 244:515–517.
16. Moen, S. J., A. A. Fryer, and R. C. Strange. 2005. Ultraviolet radiation, vitamin D and risk of prostate cancer and other diseases. Photochem. Photobiol. 81:1252–1260.
17. Webb, A. R. 2006. Who, what, where and when—influences on cutaneous vitamin D synthesis. Prog. Biophys. Mol. Biol. 92:17–25.
18. Hsu, J. Y., D. Feldman, J. E. McNeal, and D. M. Peehl. 2001. Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. Cancer Res. 61:2852–2856.
19. Flourakis, M., and N. Prevarskaya. 2009. Insights into Ca2+ homeostasis of advanced prostate cancer cells. Biochim. Biophys. Acta 1793:1105–1109.
20. Legrand, G., S. Humez, C. Slomianny, E. Dewailly, F. Vanden Abeele, P. Mariot, et al. 2001. Ca2+ pools and cell growth. Evidence for sarcoendoplasmic Ca2+-ATPases 2B involvement in human prostate cancer cell growth control. J. Biol. Chem. 276:47608–47614.
21. Liao, J., A. Schneider, N. S. Datta, and L. K. McCauley. 2006. Extracellular calcium as a candidate mediator of prostate cancer skeletal metastasis. Cancer Res. 66:9065–9073.
22. Gunnell, D., S. E. Oliver, T. J. Peters, J. L. Donovan, R. Persad, M. Maynard, et al. 2003. Are diet-prostate cancer associations mediated by the IGF axis? A cross-sectional analysis of diet, IGF-1 and IGFBP-3 in healthy middle-aged men. Br. J. Cancer 88:1682–1686.
23. Qin, L. Q., P. Y. Wang, T. Kaneko, K. Hoshi, and A. Sato. 2004. Estrogen: one of the risk factors in milk for prostate cancer. Med. Hypotheses 62:133–142.
24. Giovannucci, E. 1998. Dietary influences of 1,25(OH)2 vitamin D in relation to prostate cancer: a hypothesis. Cancer Causes Control 9:567–582.
25. Statistical Institute of Jamaica. 2009. Population Census 2001: Jamaica. Statistical Institute of Jamaica, Kingston, Jamaica.
26. Jackson, M. D., M. K. Tulloch-Reid, N. McFarlane-Anderson, A. Watson, V. Seers, F. I. Bennett, et al. 2013. Complex interaction between serum folate levels and genetic polymorphisms in folate pathway genes: biomarkers of prostate cancer aggressiveness. Genes Nutr 8:199–207.
27. Gleason, D. F., and G. T. Mellinger. 1974. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J. Urol. 111:58–64.
28. WHO. 2000. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ. Tech. Rep. Ser. 894:i–xii, 1–253.
29. Molloy Billy, J., J. Calton Lisa, P. Cooper Donald. 2009. A new semi-automated solid- phase extraction method for the high-throughput analysis of 25-hydroxyvitamin D in serum. Waters Application note, 7200031 39EN
30. Jackson, M. D., S. P. Walker, N. M. Younger, and F. I. Bennett. 2011. Use of a food frequency questionnaire to assess diets of Jamaican adults: validation and correlation with biomarkers. Nutr. J. 10:28.
31. Holick, M. F., N. C. Binkley, H. A. Bischoff-Ferrari, C. M. Gordon, D. A. Hanley, R. P. Heaney, et al. 2011. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96:1911–1930.
32. Skinner, H. G., and G. G. Schwartz. 2008. Serum calcium and incident and fatal prostate cancer risk in a large nested case-control study. Cancer Epidemiol. Biomarkers Prev. 17:2302–2305.
33. Skinner, H. G., and G. G. Schwartz. 2009. A prospective study of total and ionized serum calcium and fatal prostate cancer. Cancer Epidemiol. Biomarkers Prev. 18:575–578.
34. Halthur, C., A. L. Johansson, M. Almquist, J. Malm, H. Gronberg, J. Manjer, et al. 2009. Serum calcium and the risk of prostate cancer. Cancer Causes Control 20:1205–1214.
35. Brandstedt, J., M. Almquist, J. Manjer, and J. Malm. 2012. Vitamin D, PTH, and calcium and the risk of prostate cancer: a prospective nested case-control study. Cancer Causes Control 23:1377–1385.
36. Salem, S., M. Hosseini, F. Allameh, S. Babakooi, A. Mehrsai, and G. Pourmand. 2013. Serum calcium concentration and prostate cancer risk: a multicenter study. Nutr. Cancer 65:961–968.
37. Van Hemelrijck, M., R. Hermans, K. Michaelsson, J. Melvin, H. Garmo, N. Hammar, et al. 2012. Serum calcium and incident and fatal prostate cancer in the Swedish AMORIS study. Cancer Causes Control 23:1349–1358.
38. Bristow, S. M., M. J. Bolland, G. S. MacLennan, A. Avenell, A. Grey, G. D. Gamble, et al. 2013. Calcium supplements and cancer risk: a meta-analysis of randomised controlled trials. Br. J. Nutr. 110:1384–1393.
39. Institute of Medicine FaNB. 2010. Dietary reference intakes for calcium and vitamin D. National Academy Press, Washington, DC.
40. Huncharek, M., J. Muscat, and B. Kupelnick. 2008. Dairy products, dietary calcium and vitamin D intake as risk factors for prostate cancer: a meta-analysis of 26,769 cases from 45 observational studies. Nutr. Cancer 60:421–441.
41. Williams, C. D., B. M. Whitley, C. Hoyo, D. J. Grant, G. G. Schwartz, J. C. Jr Presti, et al. 2012. Dietary calcium and risk for prostate cancer: a case-control study among US veterans. Prev Chronic Dis 9:E39.
42. Rowland, G. W., G. G. Schwartz, E. M. John, and S. A. Ingles. 2013. Protective effects of low calcium intake and low calcium absorption vitamin D receptor genotype in the California Collaborative Prostate Cancer Study. Cancer Epidemiol. Biomarkers Prev. 22:16–24.
43. Cole, D. E., V. D. Peletkova, L. A. Rubin, G. A. Hawker, R. Vieth, C. C. Liew, et al. 1999. A986S polymorphism of the calcium-sensing receptor and circulating calcium concentrations. Lancet 353:112–115.
44. Weinstein, S. J., A. M. Mondul, W. Kopp, H. Rager, J. Virtamo, and D. Albanes. 2013. Circulating 25-hydroxyvitamin D, vitamin D-binding protein and risk of prostate cancer. Int. J. Cancer 132:2940–2947.
45. Murphy, A. B., Y. Nyame, I. K. Martin, W. J. Catalona, C. M. Hollowell, R. B. Nadler, et al. 2014. Vitamin D deficiency predicts prostate biopsy outcomes. Clin. Cancer Res. 20:2289–2299.
46. Albanes, D., A. M. Mondul, K. Yu, D. Parisi, R. L. Horst, J. Virtamo, et al. 2011. Serum 25-hydroxy vitamin D and prostate cancer risk in a large nested case-control study. Cancer Epidemiol. Biomarkers Prev. 20:1850–1860.
47. Meyer, H. E., T. E. Robsahn, T. Bjorge, M. Brustad, and R. Blomhoff. 2013. Vitamin D, season, and risk of prostate
cancer: a nested case-control study within Norwegian health studies. Am. J. Clin. Nutr. 97:147–154.

48. Travis, R. C., F. L. Crowe, N. E. Allen, P. N. Appleby, A. W. Roddam, A. Tjonneland, et al. 2009. Serum vitamin D and risk of prostate cancer in a case-control analysis nested within the European Prospective Investigation into Cancer and Nutrition (EPIC). Am. J. Epidemiol. 169:1223–1232.

49. Signorello, L. B., S. M. Williams, W. Zheng, J. R. Smith, J. Long, Q. Cai, et al. 2010. Blood vitamin d levels in relation to genetic estimation of African ancestry. Cancer Epidemiol. Biomarkers Prev. 19:2325–2331.

50. Miljkovic, I., L. M. Bodnar, J. A. Cauley, C. H. Bunker, A. L. Patrick, V. W. Wheeler, et al. 2011. Low prevalence of vitamin D deficiency in elderly Afro-Caribbean men. Ethn. Dis. 21:79–84.

51. Schwartz, G. G., and B. S. Hulka. 1990. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res. 10:1307–1311.

52. Gilbert, R., C. Metcalfe, S. E. Oliver, D. C. Whiteman, C. Bain, A. Ness, et al. 2009. Life course sun exposure and risk of prostate cancer: population-based nested case-control study and meta-analysis. Int. J. Cancer 125:1414–1423.

53. Essien, U., N. Goel, and M. L. Melamed. 2013. Role of vitamin D receptor activation in racial disparities in kidney disease outcomes. Semin. Nephrol. 33:416–424.

54. Lindeman, B. M., C. E. Pesce, H. L. Tsai, H. Somervell, C. B. Umbricht, J. Kowalski, et al. 2014. Lower vitamin D levels in surgical hyperparathyroidism versus thyroid patients. Am. Surg. 80:505–510.

55. Song, B. J., and D. C. Rockey. 2013. Status of research on vitamin D supplementation in treating or preventing liver fibrosis. Liver Int. 33:653–655.

56. Miller, G. J., G. E. Stapleton, T. E. Hedlund, and K. A. Moffat. 1995. Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1α,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines. Clin. Cancer Res. 1:997–1003.

57. Albanes, D., S. J. Weinstein, M. E. Wright, S. Mannisto, P. J. Limburg, K. Snyder, et al. 2009. Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer. J. Natl. Cancer Inst. 101:1272–1279.